Business Description
Intervacc AB
ISIN : SE0009607252
Total Employee Number:
16Compare
Compare
Traded in other countries / regions
IVACC.Sweden2E9.Germany IPO Date
2018-07-20Description
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1348.39 | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 10.45 | |||||
Beneish M-Score | -2.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -21.9 | |||||
3-Year EBITDA Growth Rate | 31 | |||||
3-Year EPS without NRI Growth Rate | 34.3 | |||||
3-Year FCF Growth Rate | 41.4 | |||||
3-Year Book Growth Rate | -39.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.99 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 93.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.38 | |||||
9-Day RSI | 78.78 | |||||
14-Day RSI | 73.99 | |||||
3-1 Month Momentum % | 185.83 | |||||
6-1 Month Momentum % | 74.55 | |||||
12-1 Month Momentum % | 27.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.46 | |||||
Quick Ratio | 6.06 | |||||
Cash Ratio | 5.9 | |||||
Days Inventory | 192.27 | |||||
Days Sales Outstanding | 23.45 | |||||
Days Payable | 99.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -71.3 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -67.82 | |||||
Operating Margin % | -488.12 | |||||
Net Margin % | -473.17 | |||||
EBITDA Margin % | -389.32 | |||||
FCF Margin % | -374.86 | |||||
OCF Margin % | -347.97 | |||||
ROE % | -29.67 | |||||
ROA % | -27.46 | |||||
ROIC % | -61.33 | |||||
3-Year ROIIC % | 23.66 | |||||
ROC (Joel Greenblatt) % | -4096.69 | |||||
ROCE % | -30.6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 24.25 | |||||
PB Ratio | 1.83 | |||||
Price-to-Tangible-Book | 3.28 | |||||
EV-to-EBIT | -3.06 | |||||
EV-to-EBITDA | -3.84 | |||||
EV-to-Revenue | 14.95 | |||||
EV-to-Forward-Revenue | 3.62 | |||||
EV-to-FCF | -4.14 | |||||
Price-to-GF-Value | 1.23 | |||||
| Price-to-Net-Current-Asset-Value | 3.28 | |||||
| Price-to-Net-Cash | 3.28 | |||||
Earnings Yield (Greenblatt) % | -32.69 | |||||
FCF Yield % | -15.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intervacc AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.726 | ||
| EPS (TTM) (€) | -0.024 | ||
| Beta | -4.4251 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.71 | ||
| Volatility % | 261.94 | ||
| 14-Day RSI | 73.99 | ||
| 14-Day ATR (€) | 0.00355 | ||
| 20-Day SMA (€) | 0.0767 | ||
| 12-1 Month Momentum % | 27.51 | ||
| 52-Week Range (€) | 0.0067 - 0.1118 | ||
| Shares Outstanding (Mil) | 340.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intervacc AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intervacc AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 126 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 42 days | ||
| General meeting for 2026 | 2026-05-13 15:00 | 0.08 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 0.08 (+0.00%) | ||
| Annual report for 2025 | 2026-04-14 | 0.06 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-16 | 0.03 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-19 | 0.03 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-29 | 0.05 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 0.08 (+38.72%) | ||
| General meeting for 2025 | 2025-05-15 | 0.08 (+38.72%) |
Show
Entries
Intervacc AB Frequently Asked Questions
What is Intervacc AB(FRA:2E9)'s stock price today?
The current price of FRA:2E9 is €0.10. The 52 week high of FRA:2E9 is €0.11 and 52 week low is €0.01.
When is next earnings date of Intervacc AB(FRA:2E9)?
The next earnings date of Intervacc AB(FRA:2E9) is 2026-08-20.
Does Intervacc AB(FRA:2E9) pay dividends? If so, how much?
Intervacc AB(FRA:2E9) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Intervacc AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers